BioCentury
ARTICLE | Clinical News

Genzyme, Pharming start Phase II/III

March 30, 2001 8:00 AM UTC

GENZ and partner Pharming (EASD:PHAR) began Phase II/III testing in the U.S. and Europe of their human alpha-glucosidase (hAG) enzyme replacement for Pompe disease. ...